At three business, we know the importance of keeping your business connected.

Whether you're doing emails on the 7.30 to Paddington or taking a video call on site,

our multi-simp plans all come with unlimited calls, texts and data.

Plus, with 99% UK coverage, you can do your best work wherever you are.

Head in store or search three business.

Unlimited UK only, 99% outdoor population coverage. Terms apply.

This is an audio long read from nature. In this episode, the controversial embryo tests that promise a better baby.

Written by Max Kozlov and read by me, Benjamin Thompson.

She has her mother's eyes, begins the advertisement, but will she also inherit her breast cancer

diagnosis? The smooth voice in the video is promoting the services of genomic prediction,

a US company that says it can help prospective parents to answer this question by testing

the genetics of embryos during fertility treatment. For Nathan

Treff, the company's chief scientific officer, this mission is personal. At 24, he was diagnosed

with type 1 diabetes, a disease that cost his grandfather his leg. If Treff had it his way,

no child would be born with a high risk

for the condition. His company in North Brunswick, New Jersey, offers tests based on a decade

of research into polygenic risk scores, which calculates someone's likelihood of getting a disease

on the basis of the genetic contributions

of hundreds, thousands or even millions of single DNA letter changes in the genome.

Genomic prediction and some other companies have been using these scores to test embryos generated

by in vitro fertilization, or IVF, allowing prospective parents to choose those with the

lowest risk for diseases, such as diabetes or certain cancers. A co-founder of genomic prediction

...